TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
Dow JonesMar 29 16:01 ET
Press Release: TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD Announces Full Year 2023 Financial Results -- Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)--March 29, 2024-- TherapeuticsMD, Inc. ("TherapeuticsMD
Dow JonesMar 29 16:00 ET
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
Dow JonesMar 29 16:00 ET
25 Countries With Highest Abortion Rates
Yahoo FinanceMar 12 11:40 ET
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indic
BenzingaDec 25, 2023 09:43 ET
TherapeuticsMD(TXMD.US) Officer Sells US$43,683.9 in Common Stocks
$TherapeuticsMD(TXMD.US)$ Officer Walker Marlan D sold 19,050 shares of Common Stocks on Dec 6, 7, 2023 at an average price of $2.2931 for a total value of $43,683.9.Source: Announcement What is state
moomoo NewsDec 7, 2023 17:30 ET
Stocks to Watch: Getty Images, TherapeuticsMD, Solid Biosciences
By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8% in after-market trading. TherapeuticsMD,
Dow JonesNov 14, 2023 18:31 ET
TherapeuticsMD Exploring Strategic Alternatives for Company
Seeking AlphaNov 14, 2023 17:29 ET
TherapeuticsMD Q3 EPS $(0.13) Misses $(0.05) Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 95.27 percent increase over losses of $(2.7
BenzingaNov 14, 2023 16:57 ET
Therapeutics MD GAAP EPS of -$0.13
Seeking AlphaNov 14, 2023 16:42 ET
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
Dow JonesNov 14, 2023 16:09 ET
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Necessary >TXMD
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Neces
Dow JonesNov 14, 2023 16:09 ET
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
Dow JonesNov 14, 2023 16:08 ET
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company
BusinesswireNov 14, 2023 16:05 ET
Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Maintains $5 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and maintains $5 price target.
BenzingaAug 17, 2023 11:48 ET
TherapeuticsMD Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 08/17/2023 39.66% Cantor Fitzgerald → $5 Reiterates Neutral → Neutral 01/11/2023 39.66% Cantor Fitzgerald
BenzingaAug 17, 2023 11:47 ET
TherapeuticsMD Q2 EPS $(0.24) Misses $(0.07) Estimate, Sales From Cont Ops $400.00K Miss $500.00K Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.07) by 242.86 percent. This is a 93.02 percent increase over losses of $(
BenzingaAug 14, 2023 06:58 ET
Therapeutics MD GAAP EPS of -$0.24
Seeking AlphaAug 14, 2023 06:52 ET
Press Release: TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD Announces Second Quarter 2023 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)--August 14, 2023-- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company
Dow JonesAug 14, 2023 06:50 ET
TherapeuticsMD 2Q Cont Ops Loss/Shr 24c >TXMD
TherapeuticsMD 2Q Cont Ops Loss/Shr 24c >TXMD
Dow JonesAug 14, 2023 06:50 ET
No Data
No Data